Drug
Lidoderm
Lidoderm: highest development phase Post-Market, developed by Endo. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Endo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lidoderm NCT00903851 | Post-Market | Diabetes |
| Lidoderm NCT00904020 | Post-Market | Postherpetic Neuralgia |
| Lidoderm NCT00904462 | Phase 2 | Osteoarthritis, Knee |
| Lidoderm (Lidocaine 5% Patch) NCT00589979 | Phase 2 | Osteoarthritis of the Knee |
Latest
No recent events.
Follow Lidoderm on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.